ONCT - Oncternal Therapeutics Adds Matthew Smith M.D. Ph.D. to its Prostate Cancer Scientific Advisory Board | Benzinga
SAN DIEGO, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (NASDAQ:ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the addition of Matthew Smith, M.D., Ph.D. to its Prostate Cancer Scientific Advisory Board (SAB). Dr. Smith, along with the other Prostate Cancer SAB members, will help guide Oncternal's next steps in the clinical development of its novel dual-acting androgen receptor inhibitor (DAARI), ONCT-534, which is currently under investigation in an ongoing Phase 1/2 clinical study, ONCT-534-101.
"We wholeheartedly welcome Dr. Smith to Oncternal's Prostate Cancer Scientific Advisory Board," said James Breitmeyer, M.D., Ph.D., Oncternal's President and CEO. "We believe Dr. Smith's expertise and his experience leading global registrational studies for novel prostate cancer therapeutics will be instrumental in helping us shape the clinical and registrational strategy for ONCT-534."
"There is a significant unmet need for patients with metastatic prostate cancer and disease progression despite treatment with currently available AR pathway inhibitors, such as abiraterone acetate and enzalutamide," said Matthew Smith, M.D., Ph.D. "I look forward to working with the Oncternal team to help bring their dual-acting AR inhibitor to patients. Preclinical studies suggest that ONCT-534 may address the most common escape mechanisms of metastatic castration-resistant prostate cancer, including activating mutations in the AR ligand-binding domain and constitutively active splice variants such as AR-V7."
Dr. Matthew R. Smith is Director of the Genitourinary Oncology Program at Massachusetts ...